OncoSec Medical Incorporated (NASDAQ:ONCS) said on Tuesday that it plans to offer for sale a combination of shares of its common stock and warrants in an underwritten public offering.
Subject to market conditions, there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
AGP/Alliance Global Partners is acting as sole book-running manager for the offering.
The late-stage cancer biotechnology company develops intratumoral gene-delivery immunotherapies, including its lead immunotherapy platform TAVO (tavokinogene telseplasmid), which enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions.
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories